AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016;63:261-83.Terrault, N.A., Bzowej, N.H., Chang, K.M., Hwang, J.P., Jonas, M.M., Murad, M.H. and American Association for the Study of Liver Diseases (2016) AASLD Guidelines for Treatment of Chronic...
2.Terrault NA, et al. Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology. 2018, 3.EASL. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017 Aug;67(2):370-398. 4.中华...
1.Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-1599.2.Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma....
3.European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol (2017), <http://dx.doi.org/10.1016/j.jhep.2017.03.021> 4.Terrault ...
内容提示: Hepatitis C Guidance 2023 Update: American Association for the Study of Liver Diseases– Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection Debika Bhattacharya, 1, Andrew Aronsohn, 2 Jennifer Price, 3 and Vincent Lo Re III...
HBeAg血清学转换后,应每隔6个月检测HBsAg HBeAg 阳性患者能用核苷(酸)类似物进行有限治疗 EASL Clinical Practice Guidelines: Management of Chronic Hepatitis B. In Press 总结(1) ? 替比夫定对慢性乙型肝炎抗病毒治疗疗效是满意的 HBeAg(+)患者24周有45%HBVDNA检测不到 2年有88%HBVDNA检测不到 e 抗原血清...
原文链接:Jing Zhang, Xiaoqing Liu, Hu Li, et al. Distribution and Liver Histopathology of Gray Zone and Corresponding Immune States in Chronic Hepatitis B Patient According to Different Guidelines. AASLD 2022 Abstract 1219
(酸)类似物进行有限治疗EASLClinicalPracticeGuidelines:ManagementofChronicHepatitisB.InPress第25页/共27页总结(1)替比夫定对慢性乙型肝炎抗病毒治疗疗效是满意的HBeAg(+)患者24周有45%HBVDNA检测不到2年有88%HBVDNA检测不到e抗原血清转换可达29%3年e抗原消失可达56%HBV复制中间体cccDNA,核苷(酸)类耗尽此复制...
Background: HBs antigen (HBsAg) loss with anti-HBs acquisition is regarded as functional cure and recognized as an ideal treatment goal for the patients with chronic hepatitis B virus (HBV) infection. However, it is difficult to achieve the functional cure in these patients by nucleos(t)ide ...
[2] Zhang J, Liu X, Li H, et al. Distribution and liver histopathology of gray zone and corresponding immune states in chronic hepatitis B patient according to different guidelines. AASLD 2022, Abstracts (1219).